Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma

Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma

<p>Cluster defining genes from scRNAseq data</p>

-д хадгалсан:

Номзүйн дэлгэрэнгүй
Үндсэн зохиолч:	Isha Mondal (16721699) (author)
Бусад зохиолчид:	Oishika Das (16721702) (author), Raymond Sun (16721705) (author), Jian Gao (16721708) (author), Bohyeon Yu (16721711) (author), Aaron Diaz (16721714) (author), Jinan Behnan (16721717) (author), Abhishek Dubey (16721720) (author), Zhipeng Meng (16721723) (author), Emad Eskandar (16721726) (author), Beisi Xu (14941098) (author), Rongze Olivia Lu (16721729) (author), Winson S. Ho (16721732) (author)
Хэвлэсэн:	2025
Нөхцлүүд:	Cancer Tumor Biology Immuno-oncology CNS Cancers Gliomas, Glioblastomas Immunology Immune responses to cancer Immunotherapy Combination immunotherapy Tumor Microenvironment Immune cells and the microenvironment
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!

Ижил төстэй зүйлс

Supplementary video from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
-н: Min Wu (14962986)
Хэвлэсэн: (2025)

Table S1 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
-н: Min Wu (14962986)
Хэвлэсэн: (2025)

Table S2 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
-н: Min Wu (14962986)
Хэвлэсэн: (2025)

Table S3 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
-н: Min Wu (14962986)
Хэвлэсэн: (2025)

Suppl video 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
-н: Andrew O. Yam (15293045)
Хэвлэсэн: (2025)

Suppl video 2 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
-н: Andrew O. Yam (15293045)
Хэвлэсэн: (2025)

Suppl video 3 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
-н: Andrew O. Yam (15293045)
Хэвлэсэн: (2025)

Suppl video 4 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
-н: Andrew O. Yam (15293045)
Хэвлэсэн: (2025)

Supplementary Table 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
-н: Andrew O. Yam (15293045)
Хэвлэсэн: (2025)

Supplementary Tables S2-13 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
-н: Francisco Hermida-Prado (14958909)
Хэвлэсэн: (2025)

Figure S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
-н: Michael Kilian (16697663)
Хэвлэсэн: (2025)

Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
-н: Michael Kilian (16697663)
Хэвлэсэн: (2025)

Figure S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
-н: Michael Kilian (16697663)
Хэвлэсэн: (2025)

Supplementary Tables S1-S4 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial
-н: Axel Stenmark Tullberg (15029928)
Хэвлэсэн: (2025)

Table S1 from HDACi-dependent Microenvironmental Normalization Overcomes Tumor Burden–induced T-cell Exhaustion
-н: Andrew Nguyen (17142197)
Хэвлэсэн: (2025)

Figure S1 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
-н: Li-Li Long (14963775)
Хэвлэсэн: (2025)

Figure S2 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
-н: Li-Li Long (14963775)
Хэвлэсэн: (2025)

Figure S3 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
-н: Li-Li Long (14963775)
Хэвлэсэн: (2025)

Figure S4 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
-н: Li-Li Long (14963775)
Хэвлэсэн: (2025)

Figure S5 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
-н: Li-Li Long (14963775)
Хэвлэсэн: (2025)

Figure S6 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
-н: Li-Li Long (14963775)
Хэвлэсэн: (2025)

Figure S7 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
-н: Li-Li Long (14963775)
Хэвлэсэн: (2025)

Supplementary Table 1 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
-н: Li-Li Long (14963775)
Хэвлэсэн: (2025)

Supplementary Table 2 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
-н: Li-Li Long (14963775)
Хэвлэсэн: (2025)

Supplementary Data from Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer
-н: Kankan Cao (16437263)
Хэвлэсэн: (2025)

Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
-н: Carlotta Antoniotti (15352506)
Хэвлэсэн: (2025)

Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
-н: Carlotta Antoniotti (15352506)
Хэвлэсэн: (2025)

Supplementary Figure S3 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
-н: Carlotta Antoniotti (15352506)
Хэвлэсэн: (2025)

Figure 1 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
-н: Clare Vesely (505402)
Хэвлэсэн: (2025)

Figure 2 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
-н: Clare Vesely (505402)
Хэвлэсэн: (2025)

Figure 3 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
-н: Clare Vesely (505402)
Хэвлэсэн: (2025)

Figure 4 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
-н: Clare Vesely (505402)
Хэвлэсэн: (2025)

Figure 5 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
-н: Clare Vesely (505402)
Хэвлэсэн: (2025)

Table 1 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
-н: Clare Vesely (505402)
Хэвлэсэн: (2025)

Supplementary Table S1 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
-н: Erika Y. Faraoni (14844897)
Хэвлэсэн: (2025)

Supplementary Table S3 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
-н: Erika Y. Faraoni (14844897)
Хэвлэсэн: (2025)

Supplementary Table S4 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
-н: Erika Y. Faraoni (14844897)
Хэвлэсэн: (2025)

Supplementary Data S1 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
-н: Maria Lozano-Rabella (15056515)
Хэвлэсэн: (2025)

Supplementary Data S2 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
-н: Maria Lozano-Rabella (15056515)
Хэвлэсэн: (2025)

Supplementary Data S3 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
-н: Maria Lozano-Rabella (15056515)
Хэвлэсэн: (2025)

Cannot write session to /tmp/vufind_sessions/sess_6e6nuj4el1969mmb76tfeajfts